Summary of "CLASE DE FARMACOVIGILANCIA"
Main ideas and concepts (pharmacovigilance class)
Purpose of pharmacovigilance
- A core tool for patient safety that focuses on drug monitoring and detecting adverse effects/reactions after exposure to medications.
- Aims to:
- Promote good pharmacovigilance practices among healthcare professionals
- Support preventive actions to avoid future harm
Foundational premise
- All drugs can produce side effects.
- Side effects should not be minimized or dismissed, because they can enable early detection and help prevent worse outcomes for future patients.
Historical catalyst and evolution
- Pharmacovigilance gained major attention after the thalidomide tragedy (1960s), when adverse reactions were not detected/recorded before widespread use.
- Risk became clearer when population changes occurred (e.g., pregnancy and exposure to drugs used for nausea/dizziness).
- Since then, pharmacovigilance has evolved from global systems to national programs and expanding scopes.
Definition and scope (WHO-related framing)
Pharmacovigilance is described as a science/discipline that:
- Detects adverse events (and whether they may develop into adverse effects)
- Evaluates how they occurred
- Implements preventive actions to avoid future exposures with related risk
Examples of risk-factor control
- Bancmycin / “vancomycin” eye syndrome
- Linked to infusion rate being too rapid
- Controlling the infusion speed resolved the effect
- Pharmacovigilance builds knowledge not only about the drug, but also about the use conditions/circumstances that lead to harm.
Expansion beyond “post-hoc” adverse effects
Includes detection/analysis of:
- Medication errors, and the need for a safety culture that evaluates errors and prevents repetition
- Quality failures, including real-world use of drugs not authorized by health authorities
- Off-label knowledge transfer (e.g., adult evidence transferred to pediatrics)
- Drug interactions (pharmacokinetic, pharmacodynamic, and chemical) causing therapeutic failure
Updates are reflected in package insert precautions/considerations.
National systems and reporting infrastructure
- Pharmacovigilance evolves into a National Pharmacovigilance System, integrating multiple actors.
- User/patient reports are possible.
- Reports converge into a database (example given: BiciFlow) where experts upload data to avoid discrepancies.
- Report entries use structured categories/subcategories to ensure consistent descriptions (e.g., standardized classification for “skin rash”).
- Scale example: ~20 million reports per year to improve patient safety and decision-making.
Role of exposure and comparison to clinical trials
- Clinical trials (phases 1–3):
- Often involve small, standardized populations
- Limited by trial design (restricted age ranges, limited concomitant conditions)
- Phase 4 / real-world use exposes many more patients with:
- More varied characteristics
- Longer and broader treatment durations
- Polypharmacy and comorbidities
- Detecting rare events improves with broader exposure, explained probabilistically (e.g., using example frequencies like “1 in 10,000” and required population size).
Late-stage and population-specific risks
- Without vigilance, late-stage reactions can be missed.
- Late effects may be mild/moderate initially but could become serious later.
- Example mentioned: adverse reactions related to COVID vaccines were detected due to attention and dissemination/communication.
- Risk profiles vary by region due to differences in:
- Genetics
- Prescribing patterns
- Manufacturing differences
- Regulation differences
Special focus areas
- Polypharmacy
- Increases the likelihood of adverse reactions, often via interactions (PK/PD)
- Drug abuse normalization
- Consider drugs of abuse, alcohol, and related interaction risks
- Alcohol can affect metabolism via enzymatic activity, changing drug behavior
- Smoking
- Includes not only nicotine but thousands of combustion substances (similar concerns for smoking marijuana)
- Herbal remedies/teas/supplements
- Common in some regions and sometimes treated as “natural and risk-free”
- But they can interact—especially in older adults
- Emphasizes gathering context:
- Patient habits, pathologies, allergy history, and all substances being used
Why pharmacovigilance is necessary even when data is limited
- The class contrasts:
- Efficacy (clinical trial outcomes) vs.
- Effectiveness (real-world outcomes), where effectiveness is much less known initially
- Pharmacovigilance helps refine the “safety profile” and guide regulatory changes.
Methodology / “how to do it” (pharmacovigilance workflow and causality)
A) Reporting approach (notification methods)
Primary tool: spontaneous reporting
- Healthcare professionals, institutions, and patients can report.
- Reports may be:
- Spontaneous/isolated case reports
- Intensive pharmacovigilance focused on higher-risk medications
- Focused studies (more complex, targeted investigations)
Where/how to report
- Reports go to the National Pharmacovigilance System (NPSA) (named in the subtitles; the class also mentions a national pharmacovigilance form available online).
- The report form serves as both:
- A documentation tool
- Guidance on what information must be collected
B) Core definitions and distinctions (important for correct reporting)
Adverse reaction / adverse drug reaction
- A harmful, unintended response with a direct correlation to the medication (used at usual dose; overdose can cause toxic effects).
Adverse effect / side effect
- Treated as an event/effect that may not have documented patient harm.
Key distinction
- Not everything harmful is automatically an “adverse drug reaction.”
- A causality study is needed to establish the likelihood of medication-related harm.
C) Causality study inputs (what to verify)
-
Confirm key temporal and usage details:
- Patient took the medication before the adverse reaction began
- Dose was appropriate/as prescribed
- Check the temporal sequence between drug, dose, and onset
-
Evaluate patient and context:
- Age, sex, comorbidities, medical history
- Concomitant medications
- Previous reactions to the same drug
- Relevant complementary tests and presumptive diagnoses
- Contextual factors such as alcohol consumption, smoking, substance abuse
-
Consider differential causality:
- Rule out other drugs, underlying pathology, or confounders
D) Severity classification (how seriousness is categorized)
- Mild
- Resolves, does not require antidote, treatment, or hospitalization
- More serious
- Interferes with daily activities, changes therapy, requires treatment
- Serious adverse reactions
- Disability, potentially life-threatening situations, requires treatment, often irreversible
E) Causality algorithm described: Naranjo algorithm
Purpose
- Assign a score supporting the strength of the hypothesis that a drug caused the adverse reaction.
Logic structure (as presented)
Evaluate questions such as:
- Timing: does the event appear after drug administration?
- Alternative explanations: can other drugs/pathology explain it?
- Dose relationship: does severity increase with dose and decrease when reduced?
- Re-exposure: does reaction reappear when re-exposed and disappear when withdrawn?
- Prior reports for the suspected drug
- Biological plausibility: is there a reasonable mechanism/argument?
Scoring concept (described)
- Conclusive prior reports add points; unknown prior knowledge adds less/zero.
- “After administration: yes” adds points; “no” subtracts.
Interpreting results via “Orange Scale”
- > 9: almost certain the drug caused the reaction
- 8–5: probable / possible (as described in subtitles)
- 4–1: improbable
- 0: very unlikely/improbable (no supportive information accumulating)
Practical note
- Reports shouldn’t be delayed for perfect information; later updates can be added.
- Peripheral experts may supplement/complete scoring using additional evaluation.
F) What to include in the report form (explicit elements listed)
Include:
- The suspected drug(s) (including concomitant medications)
- The adverse reaction/event as precisely as possible
- Any treatments given
- Relevant tests and presumptive diagnosis
- Outcomes and time course (hospitalization, duration, recovery) when known
- Patient-context details:
- Alcohol, smoking, substance abuse
- Medicinal plants/herbal remedies (e.g., teas/supplements)
Verify:
- Data accuracy
- Temporal sequence (drug → dose → event onset)
- Dose and administration correctness
G) Case-based illustration (how the process is applied)
- Example described:
- Child with epilepsy and developmental delay taking valproic acid
- Reaction: vascular papules and ecchymosis
- Onset and hospitalization documented
- Patient took medication before reaction; dose adequate
- Naranjo algorithm used to reach a “possible” adverse reaction conclusion, considering alternative drugs and patient factors.
Lessons emphasized (behavior and mindset)
- Be proactive: vigilance extends beyond prescribing/administration/dispensing.
- Don’t dismiss mild/moderate or late-onset reactions—they can predict future serious issues.
- Look at the whole patient:
- Polypharmacy
- Interactions
- Alcohol/smoking/drugs of abuse
- Herbal/supplement use
- Demographic/population differences
- Report and update:
- Spontaneous reporting is fundamental even with incomplete information.
Speakers/sources featured (as named in subtitles)
- Black (quoted regarding healthcare professionals’ responsibility in pharmacovigilance)
- World Health Organization (WHO) (2011 definition referenced)
- Dr. Valsesia (provided photographs; described as a national expert in pharmacovigilance)
- Mentioned/used tool: Naranjo algorithm (causality algorithm)
Category
Educational
Share this summary
Is the summary off?
If you think the summary is inaccurate, you can reprocess it with the latest model.
Preparing reprocess...